AAAAAA
Results: 26-32/32
Authors:
Portenoy, RK
Caraceni, A
Cherny, NI
Goldblum, R
Ingham, J
Inturrisi, CE
Johnson, JH
Lapin, J
Tiseo, PJ
Kreek, MJ
Citation: Rk. Portenoy et al., Dynorphin A(1-13) analgesia in opioid-treated patients with chronic pain -A controlled pilot study, CLIN DRUG I, 17(1), 1999, pp. 33-42
Authors:
Vogl, D
Rosenfeld, B
Breitbart, W
Thaler, H
Passik, S
McDonald, M
Portenoy, RK
Citation: D. Vogl et al., Symptom prevalence, characteristics, and distress in AIDS outpatients, J PAIN SYMP, 18(4), 1999, pp. 253-262
Authors:
Caraceni, A
Portenoy, RK
Citation: A. Caraceni et Rk. Portenoy, An international survey of cancer pain characteristics and syndromes, PAIN, 82(3), 1999, pp. 263-274
Authors:
Portenoy, RK
Payne, D
Jacobsen, P
Citation: Rk. Portenoy et al., Breakthrough pain: characteristics and impact in patients with cancer pain, PAIN, 81(1-2), 1999, pp. 129-134
Authors:
Portenoy, RK
Payne, R
Coluzzi, P
Raschko, JW
Lyss, A
Busch, MA
Frigerio, V
Ingham, J
Loseth, DB
Nordbrock, E
Rhiner, M
Citation: Rk. Portenoy et al., Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study, PAIN, 79(2-3), 1999, pp. 303-312
Authors:
Portenoy, RK
Lesage, P
Citation: Rk. Portenoy et P. Lesage, Management of cancer pain, LANCET, 353(9165), 1999, pp. 1695-1700
Authors:
Collins, JJ
Dunkel, IJ
Gupta, SK
Inturrisi, CE
Lapin, J
Palmer, LN
Weinstein, SM
Portenoy, RK
Citation: Jj. Collins et al., Transdermal fentanyl in children with cancer pain: Feasibility, tolerability, and pharmacokinetic correlates, J PEDIAT, 134(3), 1999, pp. 319-323